Abstract 131: Plasminogen Oxidized Phospholipid Adducts Drive Macrophage Activation In Through TLR2
Autor: | Danielle L Michell, Clark Massick, Chase Raby, Ashley Cavnar, Ryan Allen, Rachael Smith, Breanne Gibson, Stephanie Moore-Lotridge, Youmin zhang, Marisol Ramirez, MacRae F Linton, Quanhu Sheng, Jonathan Schoenecker, Kasey C Vickers |
---|---|
Rok vydání: | 2022 |
Předmět: | |
Zdroj: | Arteriosclerosis, Thrombosis, and Vascular Biology. 42 |
ISSN: | 1524-4636 1079-5642 |
Popis: | Oxidized phospholipids (OxPL) are potent proinflammatory mediators that can trigger toll-like receptor 2 (TLR2) signaling and inflammasome activation in macrophages. Plasminogen (PLG), a key enzyme in the fibrinolytic pathway, has been shown to harbor OxPL adducts. We hypothesized that PLG can drive inflammasome activity in macrophages through OxPL activation of TLR2 in a fibrin-independent mechanism. To assess PLG-induced macrophage activation, total RNA sequencing was used to quantify gene changes in response to human PLG treatments, and we observed robust induction of pro-inflammatory genes, including Il1b, Il6, Nos2, Il12 , and Nlrp3 in primary mouse macrophages. In addition, a 400-fold increase in IL-6 protein was observed in the media. To determine if this activation is specifically via TLR2, a HEK293-NF-kB reporter system was used to screen PLG-induced activation of human TLRs, and we found that human PLG significantly-induced NF-kB signaling and transactivation in reporter cells expressing TLR2, TL1/2, TLR2/6, but failed to activate TLRs1/3/4/5/6/9. PLG activation of TLR2 was found to be blocked by pre-treatment of C29, a small molecule inhibitor of TLR2. In addition, when Tlr2-/- primary macrophages were treated with human PLG a 30% reduction in Il1b, Il6 and Tnf gene (mRNA) expression was observed compared to wild-type controls. Furthermore, we found PLG-TLR2 activation to be fibrin-independent, as there was no reduction in PLG activation by the lysine analogs tranexamic acid and e-aminocaproic acid or the plasmin activity inhibitor - VPLCK in our HEK293-NF-kB reporter system. To characterize the effect of PLG on inflammation in vivo , wild-type and Plg-/- mice were injected with AAV8-PCSK9 and treated with an atherogenic diet for 16 weeks. Remarkably, the Plg-/- mice demonstrated reduced plaque mass and aortic lipid content compared to wild-type control mice, with a 40% reduction in en face Sudan IV staining and a 10% reduction in lesion area by Oil-Red-O staining of neutral lipids. Collectively these results support that PLG-OxPL likely activate inflammasomes in macrophages through TLR2 and suggest this is likely to be involved in atherogenesis in vivo . |
Databáze: | OpenAIRE |
Externí odkaz: |